Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae
Authors:
Open Access
- 19 August 2016
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 7, 1304
Abstract
By far, only tigecycline, colistin and some aminoglycosides still show favorable in vitro activities against carbapenem-resistant Enterobacteriaceae. However, rapid emergence of resistance often occurs during long-term treatment in clinic, challenging these last resort antimicrobials. In this study, we measured mutant prevention concentration (MPC) and mutant selection window (MSW) of tigecycline, colistin and amikacin alone and in combination for clinical isolates of KPC-producing K. pneumoniae, and characterized the resistant mutants recovered. The MPC90 of 30 tested isolates for tigecycline, colistin and amikacin were 16, >128 and 128 mg/L, respectively. The average MSW of tigecycine-amikacin, tigecycline-colisitn, and amikacin-colistin combinations for 4 representative strains were 11.99, 200.13 and 372.38, respectively. A strong correlation was found between the MSWcombination and the product of MSW of each single drug. Combinations of 1MIC multiple tigecycline and 1MIC multiple amikacin could result in 1000-10000 fold reduction in mutational frequency relative to their individual mutational frequencies, and combinations of 1 MIC multiple amikacin and 1.5-2 MIC multiple tigecycline could successfully restrict the recovery of resistant mutants on agar plates. However, 2 MIC multiple colistin in combination with 2 MIC multiple tigecycline or amikacin merely resulted in approximately 10 fold decrease in the mutational frequency. In conclusion, this study showed tigecycline-amikacin combination could effectively suppress the selection of resistance at low concentrations compared with the colistin-tigecycline and colistin-amikacin combinations, suggesting that this combination may be useful in clinical therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81371855)
This publication has 29 references indexed in Scilit:
- Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniaePLOS ONE, 2015
- Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysisThe Brazilian Journal of Infectious Diseases, 2015
- Options for treating carbapenem-resistant EnterobacteriaceaeCurrent Opinion in Infectious Diseases, 2014
- Mutant prevention concentration of tigecycline for Acinetobacter baumannii and Klebsiella pneumoniae clinical isolatesJournal of Antimicrobial Chemotherapy, 2014
- Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available EvidenceAntimicrobial Agents and Chemotherapy, 2014
- In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumanniiThe Journal of Antibiotics, 2013
- Infection with PanresistantKlebsiella pneumoniae:A Report of 2 Cases and a Brief Review of the LiteratureClinical Infectious Diseases, 2009
- Impact of Antimicrobial Usage on Antimicrobial Resistance in Commensal Escherichia coli Strains Colonizing Broiler ChickensApplied and Environmental Microbiology, 2007
- Restricting the Selection of Antibiotic‐Resistant Mutant Bacteria: Measurement and Potential Use of the Mutant Selection WindowThe Journal of Infectious Diseases, 2002
- Restricting the Selection of Antibiotic‐Resistant Mutants: A General Strategy Derived from Fluoroquinolone StudiesClinical Infectious Diseases, 2001